Latest En + Cy News & Updates

See the latest news and media coverage for En + Cy. We track all announcements, press releases, and industry mentions in real time, all in one place.

En + Cy

Clinical-stage biotechnology company developing neuroplastogens for complex pain

ensysce.com

Headquarters: La Jolla, United States
Founded year: 2008
Company type: Public company
Number of employees: 12–50
Industry: Pharmaceuticals

Last updated October 21

Latest news about En + Cy

In short: Ensysce completed its $31 million net-cash Cy Biopharma acquisition and submitted CY200’s Phase 2a CRPS protocol.

Company announcements

October 12 En + Cy

En + Cy reports on 2026 milestones and Nasdaq compliance

The company completed the Cy Biopharma acquisition for $31 million net cash and met stockholders' equity requirements, securing a bid-price extension until February 2027.

August 31 En + Cy

Ensysce advances its compliance efforts ahead of NASDAQ deadlines

The $21 million acquisition financing meets equity thresholds. Management also received a second 180-day extension for share pricing requirements while advancing new clinical programs.

August 24 En + Cy

Ensysce completes Cy Biopharma acquisition and advances clinical programs

The company integrates teams while maintaining its financial runway through late 2027, contingent on meeting clinical milestones that could extend funding.

August 10 En + Cy

Ensysce completes acquisition of Cy Biopharma

The deal adds a neuroplastogenic CRPS therapy with FDA orphan designation, $21.5M private placement, $17.1M Cy cash, and up to $38.6M on milestone.

Media coverage

October 21 Stock Titan

A severe chronic pain disorder has no FDA-approved therapy. Ensysce met investors in Dubai.

In September 2026, Ensysce submitted a protocol for a Phase 2a study of CY200 for Complex Regional Pain Syndrome (CRPS) to the UK Medicines and...

August 25 Stock Titan

Ensysce (NASDAQ: ENSC) raises $21M as it asks Nasdaq for time on $1 bid rule

Ensysce Biosciences, Inc.

January 23, 2024 MarketWatch

Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR

By Josh Beckerman Ensysce Biosciences shares rose 39% Tuesday as the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its...

June 30, 2021 The Globe and Mail

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing - The Globe and Mail

Detailed price information for Ensysce Biosciences Inc (ENSC-Q) from The Globe and Mail including charting and trades.

Never miss news about En + Cy

Track En + Cy and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

En + Cy competitors & trending companies

Browse news for competitors to En + Cy and other trending companies.